Izidlo ze-Ketogenic ze-ADHD

Izidlo ze-Ketogenic ze-ADHD

Ingabe i-Keto Ingasiza I-ADHD?

Ukudla kwe-Ketogenic kungasiza i-ADHD ngokwelapha izindawo ezimbalwa ze-pathology engaphansi ekhonjwe njengezimpawu ezibangela. Lezi zindawo zihlanganisa i-glucose hypometabolism, ukungalingani kwe-neurotransmitter, i-neurotrophic factor ephansi etholakala ebuchosheni, ukuvuvukala, nokucindezeleka okwenziwe nge-oxidative. Ukudla kwe-ketogenic okwakhiwe kahle kungabuye kuthuthukise isimo somsoco futhi kwelaphe ukungasebenzi kahle kwe-cofactor okubonwa kubantu be-ADHD.

Okuqukethwe

Isingeniso

I-Attention Deficit Disorder (ADD) kanye Ne-Attention Deficit Hyperactivity Disorder (ADHD) kubonakala sengathi kuthonywa ngokuyinhloko izakhi zofuzo kuma-80% ezimo. Nokho, njengazo zonke izakhi zofuzo, indawo ezungezile evula futhi ivale lezo zakhi zofuzo iyisici esinamandla esibizwa ngokuthi i-epigenetics. Futhi indlela yokuphila, ukudla, ukuvivinya umzimba, ukuchayeka elangeni, izindawo ezicindezelayo, ubuthi konke kuyizici ze-epigenetic eziphoqelelayo. Okusho ukuthi zingenza ezinye izakhi zofuzo ziziveze kakhudlwana kanti ezinye ziziveze kancane. Ngakho-ke into efana nokudla kwe-ketogenic, okuwukudla okunamandla kanye nendlela yokuphila ye-epigenetic factor, kungasiza ekudambiseni noma ekwehliseni ezinye zezimpawu ze-ADHD.

Kodwa ake ngicace. Awekho ama-RCT abonisa ukuthi ukudla kwe-ketogenic kuyasiza ku-ADHD naku-ADD. Kodwa kungenzeka ukuthi ziyeza maduze. Njengoba ubufakazi be-anecdotal buqhubeka bukhuphuka, izithakazelo kanye noxhaso lwezimali kuma-RCTs kungenzeka kakhulu. Yize singeke sazibona zenziwa ngamandla njengoba besingenza ezimbonini zemithi ezinamandla okwenza inzuzo ephezulu. Noma kunjalo, uma usesha ku-Reddit ye-ADHD, i-ADD, ne-Keto, uthola abantu abaningi babelana ngezindaba zabo ukuthi ukudla kwe-ketogenic kubasizile. Ungafunda ezinye zazo lapha. Futhi njengoba abaningi beke babuza ngaphambili, kungenzeka ukuthi ufikile kuleli khasi ubuza umbuzo othi “Ingabe i-keto ingasiza i-ADHD?”

Lokhu okuthunyelwe kwebhulogi kuzohlola ezinye zezindlela ukudla kwe-ketogenic kungasiza ekwelapheni ezinye zezimpawu ze-ADHD ne-ADD. Kokuthunyelwe kwangaphambilini, sihlole ukuthi ukudla kwe-ketogenic kuphatha kanjani izindawo ezine ezilandelayo eziyisisekelo ze-pathologies, ngokuvamile. Ungafunda lezi zikhala ezincane kodwa ezifundisayo lapha, lapha, Futhi lapha. Kulokhu okuthunyelwe, sizohlola lezi zindawo ezine ezifanayo ze-pathology ezibonwa ku-ADHD naku-ADD futhi sihlole ukuthi ukudla kwe-ketogenic kungase kuthuthukise izimpawu ezingase zivele kulezi zindawo zokungasebenzi kahle:

  • I-Glucose Hypometabolism
  • Ukungalingani kwe-Neurotransmitter
  • Ukuvuvukala
  • Ukucindezeleka okwexubile

Kulokhu okuthunyelwe kwebhulogi, ngizonweba lezi zindawo zokwelashwa ezingaba khona kancane ukuze ngifake ulwazi olujwayelekile mayelana ne-brain-derived neurotrophic factor (BDNF) kanye nendima yamasosha omzimba ku-ADHD/ADD. Zombili izici ezibalulekile okufanele uzihlole njengoba uzama ukuphendula ukuthi ukudla kwe-keto kungasiza yini nge-ADHD kanye ne-ADD.

Ngeke ngingene ezimpawini noma ezimeni zokuxilonga ze-ADHD ngokuningiliziwe kule bhulogi. Ayihloselwe ukuba nolwazi ngaleyo ndlela, futhi kunendatshana yezihloko ku-inthanethi ezinikeza lolu lwazi. Uma uthole le bhulogi, kungenxa yokuthi uyazi ukuthi kuyini i-ADHD ne-ADD, futhi ungase ufune izindlela zokwelapha izimpawu zakho noma zothile omthandayo.

Ungase uzibuze ukuthi ungakwazi yini ukwelapha i-ADHD ngaphandle kwemithi evuselelayo. Noma kungenzeka ukuthi uhlola ukuthi ukudla ukudla okune-ketogenic kungakuvumela yini ukuthi udinge imithi evuselelayo. Imithi encane ingaba yinzuzo, ikakhulukazi njengoba izidakamizwa zengqondo ziqeda imisoco.

Imithi yengqondo, njengaleyo esetshenziselwa ukwelapha i-ADHD ne-ADD, iqeda imisoco elandelayo:

  • magnesium
  • Iron
  • Ifolda
  • Omega 3s
  • B1, B2, B3, B6 kanye ne-B12
  • Zinc
  • CoQ10

Ukuncipha komsoco ovela ekusetshenzisweni kwemithi kuhlanganiswe nokucindezelwa kokudla okutholakala ngemithi ye-ADHD kanye ne-ADD. Ukucindezela ukudla okubangelwa ukusetshenziswa kwemithi kungabangela wena noma othandekayo ukuthi ungadli okwanele ukugcwalisa lokhu kuncipha. Ungase ufune ukukwazi ukuphuza imithi engakhuthazi kangako ngenxa yalesi sizathu kuphela. Uhlu olungenhla lokuncishiswa komsoco lubalulekile futhi luthinta ngokuqondile ukuthi ubuchopho bakho bungasebenza kanjani. Ukuthi ubuchopho bakho bungashisa amandla esenzo sokukhuluma phakathi kwama-neurotransmitters, ukunciphisa ukuvuvukala, nokuzilungisa konke kuncike enanini elanele lalezo misoco ezibalwe ngenhla.

Kuyahlekisa, ngiyazi.

Kungenzeka ukuthi ufunda le bhulogi ngoba une-ADHD noma i-ADD kuphela, noma kungenzeka ukuthi ufunda le bhulogi ngenxa yokuthi une-ADHD kanye nolunye uhlobo lwe-comorbid disorder ofuna ukukhululeka kukho. Abantu abadala abaningi abane-ADHD bahlushwa yizimo ezihambisanayo, ezihlanganisa:

  • I-antisocial personality disorder (14-24%)
    • Qaphela: ezinganeni lokhu kuxilongwa kuvame ukuba yi-Oppositional-Defiant Disorder. Uma iqhubeka idlule iminyaka eyi-18, ukuxilonga kushintshela ku-PD engahambisani nomphakathi
  • I-borderline personality disorder (14%)
  • izinkinga ezithintekayo ezinokucindezeleka (20%)
  • i-bipolar disorder (20%)
  • ukukhathazeka (kufika ku-50%)
  • i-social phobia (32%)
  • ukwethuka (15%)
  • I-Obsessive-compulsive disorder (20%)
  • ukusetshenziswa kabi kwezidakamizwa (20-30%)

Kungakhathaliseki ukuthi kungani ufunda le bhulogi, ngithemba ukuthi ekugcineni, uzoqonda kangcono ukuthi ukudla kwe-ketogenic kungaba kanjani ukwelashwa okuyinhloko noma okuhambisanayo kwezimpawu zakho ze-ADHD noma ze-ADD.

I-ADHD kanye ne-Hypometabolism

I-Hypometabolism yigama esilisebenzisa ukuchaza izindawo zobuchopho ezingawasebenzisi kahle amandla (hypo=low; metabolism=use of energy). Abantu abane-ADHD banezindawo zobuchopho ezingasebenzi ngokwanele futhi zikhonjwa njengezinobuchopho be-hypometabolism ezakhiweni ezithile. I-Hypometabolism ebuchosheni be-ADHD ibonakala ku-prefrontal cortex (ikakhulukazi kwesokudla), i-caudate nucleus, kanye ne-anterior cingulate. Singabona futhi umphumela ojwayelekile kakhulu ekuthathweni kweglucose ebuchosheni be-ADHD balabo bantu abadala abanezimpawu zokunganyakazi kahle.

I-Global cerebral glucose metabolism ibiphansi ngo-8.1% kubantu abadala abanokunyakaziswa ngokweqile kunokulawulwa okuvamile. 

Zametkin, AJ, Nordahl, TE, Gross, M., King, AC, Semple, WE, Rumsey, J., … & Cohen, RM (1990). I-cerebral glucose metabolism kubantu abadala abane-hyperactivity yokuqala yobuntwana. I-DOI: http://doi.org/10.15844/pedneurbriefs-4-11-4

Ezifundweni zezilwane, enye yezindlela ze-methylphenidate (ethengiswa njenge-Ritalin namanye amagama ezidakamizwa) ukuthi imithi yandisa ukutholwa kwe-glucose ebuchosheni. Izinkinga nge-glucose hypometabolism ezifundeni zobuchopho ezishiwo ngenhla zikhona ezinganeni, intsha, kanye nabantu abadala. Abantu abadala abatholwe bene-ADHD njengezingane banezifunda ze-glucose hypometabolism ebuchosheni njengabantu abadala.

Kukhona nobufakazi bokuthi ukuhlukahluka kofuzo yikhona okubangela ukuthi i-glucose hypometabolism yenzeke, ikakhulukazi ekusebenzeni kwama-receptors athile abalulekile njenge-GLUT3. Lapho i-GLUT3 isebenza kahle, ixhumanisa ukutholwa kwe-glucose kuma-neurons futhi itholakala ikakhulukazi kuma-axon nama-dendrites. Kodwa kubantu abane-ADHD, siyabona ukuthi i-polymorphisms yofuzo inomthelela ekhonweni le-GLUT3 lokusebenza kahle nokuthi lokhu kungase kube okuholela ezinkingeni zokuqala ze-neurocognitive okucatshangwa ukuthi zinomthelela engcupheni ye-ADHD.

Ukudla kwe-ketogenic kusiza kanjani ubuchopho be-hypometabolism ku-ADHD

Hmmm. Bekungeke yini kube kuhle uma bekukhona omunye uphethiloli wobuchopho be-ADHD/ADD? Lowo obungathembeli kushukela noma obhekane nezithuthi ze-GLUT3 ezinephutha? Ngenhlanhla kukhona! Kwenzeka ukuthi ukudla kwe-ketogenic.

Izidlo ze-Ketogenic zinikeza omunye uphethiloli wobuchopho owaziwa ngokuthi ama-ketone. Lawa ma-ketone angena ngqo ebuchosheni njengomthombo wamafutha. Azikho izinto zokuhamba ze-GLUT ezidingekayo. Ama-Ketones asebenzisa i-monocarboxylate transporters (MCTs), oyitholayo ngokudla okunempilo okunamafutha ekudleni kwe-ketogenic.

Futhi into ephambene ukuthi, ama-ketone awasizi nje kuphela i-mitochondria yakho ekhona ukuthi isebenze kangcono, kodwa akhuthaza amangqamuzana akho obuchopho ukuthi enze okwengeziwe. Futhi kuningi ongakwenza ngalokho kukhulu kokulawulwa kwamandla obuchopho. Ikakhulukazi uma kwenzeka ku-lobe yangaphambili.

Yini eyenziwa yi-mitochondria?

Njengokungathi ukunikeza omunye uphethiloli wobuchopho wobuchopho be-hypometabolic kwakunganele, ama-ketones nawo andisa i-metabolism yamandla ngokulawula i-neuronal cell mitochondria. I-Mitochondria amabhethri amaseli akho. Ake ngikucacise. Lezi mitochondria ezincane zifana ama-reactors kagesi. Igama elithi “amabhethri” aliwenzi ubulungiswa.

Kodwa linda. Kukhona okwengeziwe.

Ama-Ketones akhiqiza amandla AMANINGI kuneglucose. Ukuze sibe neqiniso, cishe 48 ATP vs. 36 ATP oyithola kuglucose.

Kukhona i-blog encane enhle yokuthunyelwe mayelana ne-ketosis, i-mitochondria, kanye nezinsimbi zokuthi ama-ketones enza kanjani i-ATP. lapha (ngiyabonga, Siimland).

Ucwaningo ludideke ngokuphelele futhi aluhambisani nokuthi iseli lidinga i-ATP engakanani, ingasaphathwa eyokuthi yiliphi izinga lamandla elidinga ingqamuzana ukuze lichume ngokuphambene nokusebenza okuncane okungenalutho. Futhi ucwaningo alucacisi ngisho nakancane ukuthi ingakanani i-ATP engasetshenziswa i-neuron evamile, i-astrocyte, noma i-glial cell. Yazi nje ukuthi ingqondo yakho isebenzisa u-70% wayo yonke i-ATP oyidalayo emzimbeni wakho wonke. Futhi uzoqala ukuqonda ukubaluleka kokufinyelela kuma-ketones njengomthombo wamandla ebuchosheni be-ADHD.

“Kodwa yima kancane!” ungase usho kimi njengoba ufunda le bhulogi. Lokhu kuhlangana ngani nezimpawu zami? I-ADHD/ADD inemibandela yokuxilonga. Futhi ingxenye yaleyo mibandela ingena ngaphansi kwalokho okubizwa ngokuthi ukungasebenzi kahle kwe-executive.

I-Executive Dysfunction, ebizwa nangokuthi ukushoda komsebenzi ophezulu noma ukuphazamiseka, yilapho ubuchopho buba nesikhathi esinzima ngamakhono okunaka, inkumbulo, ukucabanga okuguquguqukayo, kanye nokuphatha inhlangano/isikhathi.

https://www.verywellmind.com/what-is-executive-dysfunction-in-adhd-5213034

Ukungasebenzi kahle kwe-Executive kuvela kuma-lobe angaphambili aphukile. Amalobe angaphambili aphukile angavela ekulimaleni kwekhanda, unhlangothi, noma ngenxa yokungatholi uphethiloli owanele wokugijima.

Futhi lokho, umngane wami ofunda ibhulogi, ukuthi ukudla kwe-ketogenic kungaphatha kanjani i-hypometabolism yangaphambili ye-lobe eyingxenye yenqubo yesifo engaphansi kwezimpawu zakho ze-ADHD/ADD.

I-ADHD kanye Neurotransmitter Ukungalingani

Kukhona ukungalingani kwe-neurotransmitter okuningana ku-ADHD ne-ADD. Lezi zihlanganisa i-serotonin, i-dopamine, i-noradrenaline, i-glutamate, ne-GABA. Ukwengeza, kukhona ukwehla kokulawulwa okubonwa entweni ebalulekile ebizwa nge-brain-derived neurotrophic factor (BDNF). Yize ingeyona i-neurotransmitter ngokobuchwepheshe, iba nomthelela ohlelweni lwe-glutamate/GABA ngakho izofakwa.

serotonin

Umehluko ekukhulumeni kofuzo okutholakala kulabo abane-ADHD kushintsha ukusebenza kwama-serotonin receptors. Lokhu kusho ukuthi indlela ingqamuzana yezinzwa eyamukela futhi isebenzise ngayo i-serotonin ye-neurotransmitter iyashintshwa. Umehluko kulawa ma-receptors nokuthi kuthinta kanjani ukuxhumana phakathi kwezakhiwo zobuchopho kucatshangwa ukuthi kuthonya okunye ukukhubazeka kokufunda nenkumbulo esikubona kubantu abane-ADHD. Amazinga ancishisiwe e-serotonin kucatshangwa ukuthi ahlobene nezimpawu zokuthatheka ezibonwa kokunye ukubonakaliswa kwalesi sifo.  

I-Dopamine

Okunye ukungasebenzi kahle kwe-neurotransmitter okubonwa ku-ADHD i-dopamine. Izinkolelo-mbono zakuqala zaphakamisa ukuthi amazinga aphansi e-dopamine, kanye namanye ama-neurotransmitters, ayeyimbangela ye-ADHD. Lo mbono ususondele emcabangweni wokuthi inkinga ayikona ukuthi ayikho i-dopamine eyanele kodwa ngoba kunamazinga aphezulu abathuthi be-dopamine. Izithuthi ze-Dopamine zivumela i-dopamine ukuthi ingene esitokisini sezinzwa ngolwelwesi olusebenza kahle lwe-presynaptic.

Naka engiqeda kukubhala. Ukuze kusetshenziswe i-dopamine, kufanele ube ne-presynaptic membrane esebenza kahle. Lokhu kuzoba usizo ngokuhamba kwesikhathi njengoba sixoxa ngokwelashwa.

Ukuba nezithutha ze-dopamine eziningi emsebenzini kusho ukuthi i-dopamine ayihlali isikhathi eside ngokwanele ku-presynaptic cleft isikhathi esifanele. Ivacushwa kuwo wonke lawo ma-receptors. Ngeke ikwazi ukwenza into yayo!

Ngenxa yokuthi i-dopamine ayikwazi ukwenza umsebenzi wayo, umuntu one-ADHD ukuthola kunzima ukufuna injabulo futhi azizwe evuzwa ngezinto ezivame ukujabulisa usuku lonke. Baxhunywe izintambo ukuze bafune i-dopamine eyengeziwe. Kungakho abantu be-ADHD bengakwazi ukuhlakulela izinkinga ngokusetshenziswa kwe-smartphone, imidlalo yekhompiyutha, ngisho nokudla okucutshunguliwe okulutha kakhulu. Zonke izinto zenzelwe ngokucophelela ukunikeza impendulo ephezulu ye-dopamine ebuchosheni. Kunomuzwa ohlukile wokungakhululeki ngaphandle kwale misebenzi eyengeziwe evuselelayo nokudla. Konke lokhu kuholela ekubeni uzizwe ungahlaliseki, uziphathe ngokungacabangi, futhi ube nezinkinga zokunakwa.

Phakathi kwezici ze-neuro-chemical, kukhona i-dysregulation eyaziwayo ekukhiqizeni ama-neurotransmitters; Ngokuyinhloko i-dopamine ne-nor-adrenaline.

Fayed, NM, Morales, H., Torres, C., Coca, AF, & Ríos, LF Á. (2021). I-Brain Magnetic Resonance Imaging in Attention-Deficit/Hyperactivity Disorder (ADHD). https://link.springer.com/chapter/10.1007/978-3-030-61721-9_44

Izinguquko eziningana zofuzo ezihlukene zinomthelela ezindabeni zomsebenzi we-dopamine obonwa kulabo abane-ADHD ne-ADD. Kucatshangwa ukuthi ukuhlukahluka kwezakhi zofuzo ngamazinga ahlukahlukene kunomthelela kuzo zonke izethulo eziningi zokugula esizibona kubantu ngabanye. Isibonelo, ama-polymorphisms e-COMT athinta uhlelo lwe-dopaminergic ahlotshaniswa kakhulu nezimpawu ze-ADHD kanye nokonakala komphakathi.

I-Norepinephrine

I-Norepinephrine iyi-neuromodulator enendima ebalulekile, kanye ne-dopamine, ekuvumeleni i-prefrontal cortex ukuthi isebenze. Khumbula, sixoxe nge-prefrontal cortex nokuthi yenzani ngaphambili kulokhu okuthunyelwe kwebhulogi. I-prefrontal cortex engasebenzi kahle izoholela ekushoda ekusebenzeni okuphezulu okuvame ukuba isigaba esingaphansi sezimpawu ezibonwa ekuxilongweni kwe-ADHD/ADD.

Yize iningi locwaningo lithanda ukugxila ku-dopamine, amathonya e-norepinephrine ku-prefrontal cortex anamandla ngendlela emangalisayo futhi ahambisana ngendlela emangalisayo ekuqondeni izimpawu ze-ADHD. Uma i-norepinephrine isebenza kahle, isiza ngenkumbulo yokusebenza nokunaka. Abantu abane-ADHD/ADD babika izinkinga ezinkulu ngenkumbulo yokusebenza nokunaka.

Siyazi ukuthi i-norepinephrine ibandakanyeka, ngokwengxenye, ngoba imithi ekhethiwe ye-noradrenergic (isb, i-clonidine, i-guanfacine) ingasiza ekwelapheni i-ADHD.

Futhi futhi, sibhekene nenkinga yabathuthi. Akukhona ngempela ukuthi kukhona i-norepinephrine eningi kakhulu noma encane, kodwa ukuthi sibona ukuhlukahluka kofuzo okuthonya ukuthi lokho osekukhona kakade kuhanjiswa futhi kusetshenziswe kanjani. Futhi futhi, siyabona ukuthi umehluko othile wofuzo obonwa ku-ADHD naku-ADD uyathinteka endleleni i-norepinephrine transporter (NET) esebenza ngayo.

I-Glutamate ne-GABA

Sixoxa ngalawa ma-neurotransmitter amabili ndawonye ngoba ayingxenye yesistimu enhle esebenza ndawonye. Ku-ADHD, sibona ukungalingani kulolu hlelo lwe-neurotransmitter. Amazinga e-Glutamate ku-prefrontal cortex, isibonelo, azothonya ngokuqondile amazinga e-dopamine kanye ne-vice-a-versa.

Kwezinye izifo ze-neurodevelopmental, njenge-ADHD, sibona ukungalingani phakathi kwe-excitatory glutamate neurotransmitter kanye ne-GABA evimbelayo. I-dopamine receptor (DRD4) ukungasebenzi kahle okubonwa ku-ADHD kudala indawo lapho kukhona i-glutamate eyengeziwe ebuchosheni. Futhi asifuni ithoni ye-glutamate elenga nje ebuchosheni, ingalinganisiswa yi-GABA. Ngoba isikhathi eside, lokhu kubangela ukulimala kwamangqamuzana obuchopho nezakhiwo zobuchopho.

I-Glutamate iwuphawu olubalulekile lobuchopho be-neurotoxic. Ukweqisa kwe-glutamate kungadala ukufa kwe-neuronal ngezinqubo ze-excitotoxic. Kuphinde kucatshangwe ukuthi i-glutamate kumasekethe angaphambili iyisilawuli esibalulekile se-dopamine, futhi ngokusebenzisa indlela yokuphendula ukugxila kwe-dopamine kungathonya ukugcwala kwe-glutamate.

Fayed, NM, Morales, H., Torres, C., Coca, AF, & Ríos, LF Á. (2021). I-Brain Magnetic Resonance Imaging in Attention-Deficit/Hyperactivity Disorder (ADHD). Ku I-Psychiatry kanye Neuroscience Update (amakhasi 623-633). Springer, Cham

Izingane ezine-ADHD zibonisa ukulawulwa okuvimbezelayo okubuthakathaka futhi yehlise kakhulu i-GABA ku-striatum, okuyisakhiwo sobuchopho esibandakanyekayo kokubili ekunqumeni ukuthi yiziphi izenzo okufanele zenziwe nokufunda mayelana nokuthi yiziphi lezo zenzo okufanele ziphindwe. Amazinga ampofu noma ukusetshenziswa kwe-GABA kucatshangwa ukuthi kunesandla ezimpawu zokuthiywa kokuziphatha ezibonwa ku-ADHD.

Umnikelo walolu hlobo oluthile lokungalingani kwe-neurotransmitter awuncane. Futhi imiphumela yalawa ma-neurotransmitters amabili ukungabi nabhalansi kucatshangwa ukuthi inomthelela ngqo ku-etiology ye-ADHD kanye nemiphumela ye-neurobiological ephikelelayo ekubeni abantu abadala.

I-brain-derived neurotrophic factor (BDNF)

I-BDNF itholakala ukuthi yehlisiwe ku-ADHD. Okunye kwalokhu kungase kube ngenxa yokuhlukahluka kofuzo okutholakala kulesi sibalo sabantu. Futhi abantu abane-ADHD/ADD bazizwa lokhu kunikezwa okunganele. Ngoba i-hippocampus yakho, isakhiwo sobuchopho esiza ukucubungula izinkumbulo zesikhashana, sisebenza kakhulu, futhi sidinga i-BDNF eningi ukuze isebenze kahle. Futhi lokhu kuncipha kwalesi sidakamizwa kungase kube isizathu esenza sibona izinkinga ngenkumbulo yesikhashana nesebenzayo kubantu abane-ADHD. Udinga futhi i-BDNF eyanele ukuze ufunde nje ngokujwayelekile. Uyidinga ukuze usayine kuma-synapses e-glutamatergic kanye ne-GABAergic (ergic=making), futhi idlala indima ekudlulisweni kwe-serotonin ne-dopamine phakathi kwamaseli. Okubalulekile ukuthi abantu abane-ADHD abanalo okwanele kwalezi zinto ezinhle. Futhi sidinga ukuthola indlela yokuyandisa.

Ukudla kwe-ketogenic kusiza kanjani ukungalingani kwe-neurotransmitter okubonwa ku-ADHD

Ngakho-ke ukudla kwe-ketogenic kungathuthukisa kanjani izimpawu ze-ADHD? Phela, kubukeka sengathi i-ADHD iningi lofuzo. Ukudla kwe-ketogenic kungakushintsha kanjani ukubonakaliswa kwezakhi zofuzo ezinquma ukuthi ama-neurotransmitters ethu asebenza kanjani (noma angasebenzi)? Ukwelashwa kokudla kungayishintsha kanjani into enkulu njengaleyo?

I-Dopamine, i-Noradrenaline, ne-Serotonin

Kungenzeka ngike ngakusho lokhu ngaphambili, kodwa kunezinhlobo ezintathu zama-ketone. Enye yalezo zinhlobo ibizwa nge-beta-hydroxybutyrate (βHB). I-βHB ikhiqiza ngaphezulu kwe-enzyme emaphakathi kumetabolism (ukukhiqizwa kwamandla) ebizwa ngokuthi i-nicotinamide adenine dinucleotide (NADH). Lokhu ikwenza ngokusebenzisa indlela eyinkimbinkimbi ongayibheka lapha (bheka Umfanekiso 3) uma unentshisekelo kulelo zinga.

Ngezinjongo zethu lapha, kubalulekile ukwazi ukuthi lokhu kwandisa ukuhlanganiswa kanye/noma umsebenzi wama-neurotransmitters i-dopamine, i-noradrenaline, i-serotonin, ne-melatonin.

Futhi uma ukhumbula ukufunda kwakho ngenhla, ukuhlukahluka kofuzo kuma-neurotransmitter expression kanye ne-transporter expression ye-serotonin, i-dopamine, ne-norepinephrine yizinkinga ezibonwa ngobuchopho be-ADHD. Ukwenza okuningi kokunye kungaba yinzuzo kakhulu.

  • Ukwenyuka kwe-serotonin kungathuthukisa ukuthatheka, ukufunda nokukhubazeka kwenkumbulo
  • Ukwenyuka kwe-dopamine kungadambisa ukungahlaliseki futhi kuthuthukise ukunaka
  • Ukwenyuka kwe-norepinephrine kungathuthukisa inkumbulo yokusebenza nokunaka

Kungaba nobuhle obuningi be-neurotransmitter obuzohambahamba, futhi kungasho ukuthi kungenzeka kube nokunye okuzohlala kukhona kuma-synapses lapho bengenza khona umlingo wabo. Futhi lokhu kulawulwa kwama-neurotransmitters abalulekile kwenziwa ngendlela elinganiselayo ngokudla kwe-ketogenic.

Ngokungafani nemithi lapho ama-neurotransmitters athile anyuswa khona noma enziwa ukuthi ahlale isikhathi eside ngangokunokwenzeka kuma-synapses, ngeke kube nemiphumela emibi yemithi. Sonke sazi kahle, isibonelo, ngemiphumela engemihle abantu abayitholayo lapho bethatha ama-SSRIs ukwandisa isikhathi sokuhlala kwe-serotonin kuma-synapses azosetshenziswa. Siyazi ukuthi i-gabapentin, eklanyelwe ukukhulisa amazinga e-GABA ebuchosheni ingadala imiphumela emibi yokozela, isibonelo. Lolu hlobo lwento alwenzeki nje ekudleni kwe-ketogenic.

Kodwa kuthiwani nge-glutamate ne-GABA?

Njengoba kuxoxiwe ngenhla, ingqondo ye-ADHD idonsa kanzima nge-glutamate eningi kanye ne-GABA encane kakhulu. Ukudla kwe-Ketogenic kungakhuphula ukusebenza kwe-glutamic acid decarboxylase, ekhuthaza ukuhlanganiswa kwe-GABA futhi iphinde iguqule umsebenzi we-enzyme ogcina i-GABA izungeza isikhathi eside kuma-synapses. Ngakho-ke ebuchosheni be-ADHD, lokhu kusho ukufinyelela okwengeziwe ku-neurotransmitter evimbelayo edingekayo ukusiza ukulinganisa amazinga aphezulu e-glutamate.

Ezifundweni zezilwane, enye yezinhlobo zemizimba ye-ketone eyaziwa ngokuthi i-acetoacetate yatholwa ukunciphisa ukuhanjiswa kwe-neurotransmission e-hippocampal synapses, okungase kuthuthukise noma okungenani kuvikele umsebenzi wenkumbulo. Abantu abane-ADHD kanye ne-ADD bavame ukukhononda ngezinkinga zenkumbulo yesikhashana nokufunda. Ukulinganisa ukusebenza kwe-neurotransmitter ezakhiweni zenkumbulo ezibalulekile ezifana ne-hippocampus kungase kube usizo ekwehliseni izimpawu.

Ukusebenza kweMembrane kanye nebhalansi ye-neurotransmitter

Awukwazi nje ukuba nengxoxo mayelana nebhalansi ye-neurotransmitter ngaphandle kokuxoxa ngomsebenzi we-neuronal membrane. I-βHB isiza ulwelwesi lwe-neuronal ukuthi luphinde lubonakale, futhi lelo khono elithuthukisiwe lokuphindaphinda linezinzuzo eziningi zobuchopho be-ADHD/ADD.

Ukwenziwa kabusha kwe-neuronal membrane, okuthuthukisiwe yi-βHB kuvumela ingqamuzana ukuthi liqongelele imisoco (ngokuvamile entula ebuchosheni be-ADHD/ADD) ukuze yenze ama-neurotransmitters kwasekuqaleni. Khumbula ngenkathi sixoxa ngezinkinga nama-neurotransmitter receptors kanye nabathuthi kubuchopho be-ADHD/ADD?

Nokho, ukwakhiwa kwama-enzyme anquma ukuthi ingakanani i-neurotransmitter ethola ukulenga ku-synaptic cleft, futhi isikhathi esingakanani into enqunywa ulwelwesi kabusha lwe-membrane. Amandla e-synaptic clefts okuhlala ezwela kuma-neurotransmitters avelayo (afana ne-dopamine, i-serotonin, ne-norepinephrine) nawo ancike ekusebenzeni kabusha kokusebenza okunempilo.

I-brain-derived neurotrophic factor (BDNF)

Izidlo ze-Ketogenic ziyaziwa ngokulawula ukukhiqizwa kwe-BDNF. Kucatshangwa ukuthi lokhu kungase kube indlela ebalulekile ebavumela ukuba bathuthukise ukuphazamiseka okuhlukahlukene kwemizwa, njengokulimala kobuchopho okubuhlungu (TBIs) kanye nokuwohloka komqondo. Ama-ketones alawula i-BDNF endimeni yawo njenge-molecule ekhombisayo, avula futhi avale izakhi zofuzo ngendlela yokuthi kudaleke okwengeziwe kwalokhu. Ngakho-ke ukukhiqiza ama-ketones, ekudleni kwe-ketogenic, kungadala i-BDNF eyengeziwe ebuchosheni be-ADHD/ADD.

Izakhi zofuzo aziwona ukudalelwa

I-ADHD ibhekwa njengethonywe kakhulu izakhi zofuzo. Futhi noma nini lapho kuxoxwa ngesifo ngaleyo ndlela, abantu bangathola umbono ongalungile mayelana nokuthi bangakwazi yini “ukulungisa” noma ukulungisa ama-pathologies angaphansi ahambisana nesimo.

Asazi ukuthi zingakanani izinkinga ngalezi zinto ku-ADHD zivela ekusebenzeni kolwelwesi lwe-neuronal okungasebenzi ngenxa yezici ze-epigenetic (isb, i-hypometabolism ngenxa yokudla, ukushoda kwe-micronutrient, neuroinflammation engapheli, ingcindezi ye-oxidative).

Noma izinkinga ngama-receptors kanye nabathuthi kuthiwa zenzeka ezingeni lofuzo kulabo abanobuchopho be-ADHD, ngifuna ukuqhubeka ngikhuluma engicabanga ukuthi kungenzeka ukuthi ukuguqula indawo lapho lezo zakhi zofuzo zivezwa khona kungasho ukuthuthuka kwezimpawu. . Indlela ukubonakaliswa kofuzo okwenzeka ngayo kubathuthi be-serotonin, i-dopamine, kanye ne-norepinephrine nama-receptors kungase kuvumeleke kumathonya e-epigenetic.

Futhi ukungenelela kwe-epigenetic, njengokudla kwe-ketogenic, kunamandla kakhulu ekuthonyeni ukubonakaliswa kofuzo. Ama-ketone angama-molecule abonisayo, okusho ukuthi anamandla okuvula nokuvala izakhi zofuzo. Ukuthi utshelwe ukuthi okuthile kuwufuzo akusho ukuthi awunawo amandla okwenza izinguquko ukuze ulungise ukuthi leyo nkulumo yenzeka kanjani.

I-ADHD kanye Neuroinflammation

Abantu abane-ADHD banamazinga abalulekile e-neuroinflammation eza kubo evela ezindaweni eziningi ezahlukene. Ukuvuvukala kungabangelwa izizathu ezihlukahlukene. Ukudla okuphezulu ku-fructose (lezo ziphuzo ezinoshukela esitolo esitholakala kalula) kungandisa ukuvuvukala. Ukungcola kungandisa ukuvuvukala. Umgoqo ovuzayo wegazi nobuchopho ovumela ubuthi bungene ebuchosheni bungabangela ukuvuvukala. Izingcindezi ezinzima, njengokuthatha isivivinyo noma ukufutha isondo kuthelawayeka, kungandisa ukuvuvukala. Futhi ukungasebenzi kwamasosha omzimba kungandisa ukuvuvukala. Naka okokugcina ngoba ukuvuvukala okubangelwa ukungasebenzi kahle kwamasosha omzimba kubonakala kusebenza kakhulu ku-ADHD.

Ngakho kusho ukuthini lokho? Lapho amasosha ethu omzimba esebenza, into ebizwa ngokuthi ama-cytokines ibe isikhiqizwa. Lawa ama-molecule amancane atshela amasosha omzimba ukuthi enzeni ukuze agcine “umuntu omubi” abasanda kutshelwa ukuthi ukhona emgqeni. Kodwa ama-cytokines awacashile lapho elwa nabahlaseli abahlukene. Benza umonakalo omkhulu. Cabanga ngesiphithiphithi esijaha amaphoyisa kanye nawo wonke umonakalo owenzekayo njengoba elandela umuntu omubi ngomfutho omkhulu kanye nesivinini esikhulu.

Yileyo ndlela ama-cytokines ahamba ngayo. Bangase babambe noma bangamtholi umuntu omubi, futhi kukhona ukungcola okukhulu okuvuvukala okumele kuhlanzwe. Futhi kuthatha umsebenzi omningi, izinto zokusebenza, nezinsiza ukwenza lokho kuhlanza. Ngobuchopho, lokho kusho amathani wamandla asetshenzisiwe (umsebenzi), amanye amangqamuzana anempilo futhi angakwazi ukucosha ukuxega (impahla), kanye nama-micronutrients (izinsiza) eziningi kakhulu kunalokho okungenzeka ukuthi uthola ekudleni kwakho.

Manje ake ucabange izimoto eziningi ezijahwa ngaso sonke isikhathi, njengokungami (okungapheli). Ekugcineni, ukuhlanza nokulungisa kuzosala ngemuva. Idolobha nomgwaqo kuzoqala ukubukeka njengesiphithiphithi esishisayo. Lokho ubuchopho bakho obubhekene ne-neuroinflammation engapheli.

Nansi indatshana enhle enweba lesi sifaniso ngendlela ekusiza ukuthi uqonde i-neuroinflammation kanye nengcindezi ye-oxidative, nokuthi zihlobana kanjani!

Ukube Ubuchopho Bakho BekuyiDolobha: Ukuqonda Ukucindezeleka Kwe-Oxidative kanye Neuroinflammation

Indlela engcono kakhulu engingabonisa ngayo ukuthi ukuvuvukala kubaluleke kangakanani ku-ADHD ukuhlinzeka ngengcaphuno evela esihlokweni socwaningo engisidonsile ukuze ngibhale lokhu okuthunyelwe.

Nakuba busalinganiselwe, lobu bufakazi buhlanganisa i-1) i-comorbidity yamathuba angenhla ye-ADHD enezinkinga zokuvuvukala kanye ne-autoimmune, i-2) izifundo zokuqala ezibonisa ukuhlangana ne-ADHD kanye nokwanda kwe-serum cytokines, 3) ubufakazi bokuqala obuvela ezifundweni zofuzo ezibonisa izinhlangano phakathi kwama-polymorphisms ezakhini zofuzo ezihambisanayo. ngezindlela zokuvuvukala kanye ne-ADHD, 4) ubufakazi obuvelayo bokuthi ukuchayeka empilweni yangaphambi kwesikhathi ezintweni eziningi eziyingozi zemvelo kungase kwenyuse ubungozi be-ADHD ngokusebenzisa indlela yokuvuvukala, kanye 5) nobufakazi bemishini obuvela kumamodeli ezilwane okuvuselelwa komzimba komama obhala imiphumela yokuziphatha nemizwa ehambisanayo. I-ADHD.

U-Dunn, GA, Nigg, JT, & Sullivan, EL (2019). I-Neuroinflammation njengesici esiyingozi sokunaka ukushoda kwe-hyperactivity disorder. https://doi.org/10.1016/j.pbb.2019.05.005

Ngakho ake sibuyekeze ukubaluleka kwalokho esisanda kukufunda. Abantu abane-ADHD banamathuba amaningi okuba ne-comorbidities yokuvuvukala kanye ne-autoimmune disorder. Ngamanye amazwi, kukhona okungalungile ngesimiso sokuzivikela komzimba, futhi kubangela ukuvuvukala ngenxa yalokho. Ngakho-ke akumangazi, lapho behlola abantu abane-ADHD ngezimpawu zegazi zokuvuvukala, bathola ukuthi banama-cytokine amaningi avuvukalayo kunezilawuli.

Uma sibheka izici zokuthuthuka ze-ADHD, sibona ukuchayeka kwentsha ezingozini zemvelo ezibangela ukuvuvukala. Kumamodeli ezilwane, baye bahlonza izindlela phakathi kokusebenza kwamasosha omzimba ngesikhathi sokukhulelwa kanye noshintsho olulandelayo lobuchopho nokuziphatha enzalweni efana naleyo ebonwa kubantu abane-ADHD.

Uma konke lokho akwanele ukukuqinisekisa ukuthi i-neuroinflammation ibaluleke kakhulu ku-ADHD, ngivumele ukuthi ngikutshele mayelana ne-polymorphisms yofuzo abatholile ehlotshaniswa nezindlela ezidala lokho kuvuvukala.

Ukuthi zonke lezi zinhlangano zitholakala zinembangela noma cha, ngingaphikisa, akunandaba. Asikho ngaphansi kwembangela yezinto eziningi, futhi sishaya ikhemisi phezulu ukuze silungise esicabanga ukuthi kuyenzeka, futhi sikwenza ngaso sonke isikhathi. Ngakho-ke kungani singacabangi ukuvuvukala njengento engaba khona ukusiza ukunciphisa izimpawu ze-ADHD?

Ngenhlanhla, abacwaningi abaningi abahlakaniphe ngempela sebevele bavumelana nami. Ngeke ngithande ukuthi ucabange ukuthi le nto nje engiyiqhamuke ngedwa.

Ngokusekelwe kumbono wethu, ukukhomba i-neuroinflammation kungase kusebenze njengendlela yokungenelela entsha yokwelapha ukwelapha i-ADHD.

Kerekes, N., Sanchéz-Pérez, AM, & Landry, M. (2021). I-Neuroinflammation njengesixhumanisi esingaba khona phakathi kwe-attention-deficit/hyperactivity disorder (ADHD) kanye nobuhlungu. https://doi.org/10.1016/j.mehy.2021.110717

Le neuroinflammation iphinde isebenze kulokho esikufunda esigabeni sokugcina mayelana nokungalingani kwe-neurotransmitter. Ukuvuvukala kudala ama-neurotransmitters ajabulisayo futhi kukhuthaza ukucasuka esikubonayo phakathi kwe-glutamate ne-GABA. Ukuvuvukala kudala indawo ebuchosheni lapho kungakwazi ukwenza izilinganiso ezifanele ze-GABA ku-glutamate. Kungenzeka ukuthi kungenxa yokuthi iphoqwa (kusuka kuzo zonke lezo zimoto ezijahwayo ezingami).

Akunangqondo ukucabanga ukuthi uzobe wenza ama-neurotransmitters akutshela ukuthi wehlise umoya futhi yonke into ihamba kahle uma une-neuroinflammation engapheli. Yingakho kubalulekile ukunaka izimpawu zakho. Kuyindlela yobuchopho bakho yokukutshela ukuthi kukhona okungahambi kahle. Idinga ukuthi ungazibi ukujahwa kwezimoto ezingami okwenzekayo nokwenza umonakalo. Kudinga ukuthi unake. Cishe akuyena umlandeli wakho ozama ukuthola imiyalelo ekusiza wenze sengathi umonakalo awenzi.

Masenze ukuvuvukala kube okunye okuhlosiwe okubalulekile kokungenelela esikubona kunomthelela ezimpawu kubuchopho be-ADHD/ADD.

Izidlo ze-ketogenic ziyindlela yokwelapha ye-neuroinflammation ebonwa ku-ADHD

Njengoba sixoxile ngenhla, i-neuroinflammation ebonwe ku-ADHD ivela ngokwengxenye ekuphenduleni kokuzivikela komzimba okungasebenzi. Angivamile ukuxoxa ngemiphumela yokudla kwe-ketogenic kumasosha omzimba, kodwa kubonakala kuhambisana kakhulu ne-etiology kanye nokwethulwa kwezimpawu nalesi sibalo.

Nokho, angifundanga kahle ezimisweni zokuzivikela ezifweni, ngakho-ke ngizoba ovamile lapha futhi ngenze ucwaningo olwengeziwe uma uzwa isidingo.

Izidlo ze-Ketogenic zilawula futhi zilinganise umsebenzi wokuzivikela komzimba. Siwasebenzisela ukusiza ukwelapha izinhlobo ezithile zomdlavuza, ngokwengxenye, ngenxa yokusabela okuhle kwamasosha omzimba ekusebenzeni kwe-T-cell. Abacwaningi bathola imiphumela emihle eyanele yokudla kwe-ketogenic ekusebenzeni kwamasosha omzimba okwaqalwa i-RCT ukubona ukuthi ingasetshenziswa yini ukunikeza isici sokuzivikela ngokumelene ne-COVID.

Abanye abantu bacabanga ukuthi lokhu kulawulwa kwamasosha omzimba kwenzeka ngenxa yezinguquko zokudla kwe-ketogenic ku-gut microbiome. Enye yezibaseli ezithandwayo zamathumbu i-butyrate, ingxenye yemizimba ethile ye-ketone futhi ingatholakala ngamanani aphezulu kubhotela. Ngihlala ngithola ukuthi lokhu kuyindida kakhulu, njengoba kugxilwe kuze kube manje kubonakala sengathi konke mayelana ne-prebiotic fiber njengeqhawe lezempilo nempilo yamathumbu. Kufanele futhi ngiveze ukuthi okunye ukuphulukiswa kwenzeka emgodleni wegazi-ubuchopho lapho uhamba ekudleni kwe-ketogenic.

Ngakho-ke, imiphumela enenzuzo yokudla kwe-ketogenic ingase incike ekuthathweni kobuchopho okwandisiwe kwama-KB ukuze kufane nesidingo se-metabolic kanye nokulungiswa kwe-BBB ephazamisekile. Njengoba imiphumela yama-KB ku-BBB nezindlela zawo zokuthutha kuyo yonke i-BBB ziqondwa kangcono, kuzokwaziwa ukwenza amanye amasu okuthuthukisa izinzuzo zokwelapha zama-KB zokuphazamiseka kwengqondo lapho i-BBB isengozini.

(KBs=imizimba ye-ketone; BBB=isithiyo sobuchopho begazi)
Banjara, M., & Janigro, D. (2016). Imiphumela yokudla kwe-ketogenic kusithiyo segazi nobuchopho. 
I-DOI: 10.1093/med/9780190497996.001.0001

Umgoqo onempilo wobuchopho begazi usho izinto ezimbalwa ezintanta phezulu ziye phezulu ebuchosheni bakho okungezona ezakho. Futhi uma unobuthi noma izinto ezidlula kulowo mgoqo wegazi nowobuchopho okungewona owakhe, kuholela ekucushweni kwama-cytokines futhi kube nomthelela ku-neuroinflammation.

Ngakho-ke cabangela imiphumela yokudla kwe-ketogenic enawo ekusebenzeni komzimba njengebhonasi edlala indima ebalulekile ekusizeni ukuthi unciphise izimpawu zakho ze-ADHD/ADD zisiza ukunciphisa izimpawu zakho.

Enye indlela ukudla kwe-ketogenic okunciphisa ngayo ukuvuvukala ngokuvimbela izindlela zokuvuvukala. Ama-ketones, enziwe ngobuningi ekudleni kwe-ketogenic, angama-molecule abonisa, futhi ukuba i-molecule ekhombisayo kusho ukuthi asebenza njengesithunywa, etshela ezinye izakhi zofuzo ukuthi zicime nezinye izakhi zofuzo zivule. Futhi ukudla kwe-ketogenic kunciphisa ukuvuvukala ngale ndlela epholile kakhulu. Njengokuthi, ngqo.

Esigabeni esilandelayo, sizofunda ngokuthi ukuvuvukala kuyidlala kanjani indima ekucindezelweni kwe-oxidative nokuthi ukwehla kwalesi simiso se-pathological kungazithinta kanjani izimpawu esizibona ku-ADHD.

I-ADHD kanye ne-Oxidative Stresss

Ukucindezeleka kwe-oxidative kwenzeka lapho kukhona ukungalingani kwekhono lomzimba lokubhekana nemikhiqizo eyenzeka ngokuphila nje. Izinto eziningi zingabangela ukucindezeleka okwenziwe nge-oxidative. Ukuphefumula nje kudala into ebizwa nge-reactive oxygen species (ROS). Ngakho umzimba wakho ulindele inani elithile le-ROS, kusukela nje usaphila. Futhi akuyona inkinga uma amasistimu wakho wokulimala/ama-antioxidant ebhalansi. Njengoba sizokhuluma kamuva kulokhu okuthunyelwe kwebhulogi, senziwe ukuthi sibhekane ne-ROS, okungenani ngezinga elithile. Kodwa amazinga esidalulwa kuwo namuhla awakaze abe khona emlandweni wakho wokuziphendukela kwemvelo.

Sisanda kuxoxa ngokuvuvukala. Ingabe ukuvuvukala kwenza ukucindezeleka okwenziwe nge-oxidative? Yebo. Yebo, kuyenzeka ngempela.

Inqubo yokuvuvukala idala ukucindezeleka kwe-oxidative futhi inciphisa umthamo we-antioxidant weselula.

Khansari, N., Shakiba, Y., & Mahmoudi, M. (2009). Ukuvuvukala okungapheli kanye nokucindezeleka okwenziwe nge-oxidative njengembangela enkulu yezifo ezihlobene nobudala nomdlavuza. https://doi.org/10.2174/187221309787158371

Lawa ma-ROS kufanele akhishwe ubuthi noma angasebenzi. Futhi ukuze umzimba wakho wenze lokho, udinga ama-micronutrients amaningi (ama-cofactors) kanye nezinga elihle lakho kokubili okungapheli (okwenziwe ngaphakathi komzimba wakho) ama-antioxidants. Abantu futhi badla ama-antioxidants (isb, i-turmeric, i-quercetin, amavithamini C no-E), ezama ukwehlisa ingcindezi ye-oxidative.

Ukucindezeleka kwe-oxidative akulona ihlaya. Uma uvunyelwe ukusebenza ungahloliwe ngokuhamba kwesikhathi, uthola umonakalo ku-DNA yakho. Ake sibuyele esifanisweni sethu sokujaha izimoto. Kungathi ukujahwa kwezimoto sekuphume esandleni kangangokuthi izakhiwo ziyawa, nemigwaqo ibhidlika. Kodwa manje, ulwazi lokulungisa zonke lezi zinto lulahlekile kuzo zonke izinxushunxushu. Futhi manje abantu abazama ukwakha kabusha idolobha, ngemuva kwakho konke lokho kujaha izimoto, abakwazi ukukwenza kahle noma ngendlela ezinzile. Lesi isifaniso sokulimala kwe-DNA okwenzeka ngengcindezi ye-oxidative engahloliwe. Njengoba ungacabanga, izifo ezingapheli zizokhula ngenxa yalokhu.

Kunezindlela eziningi ezihlukene ukuthi i-ROS eyengeziwe idalwe kunalokho umzimba wethu ongakwazi ukuyiphatha. Ngaphandle nje kokuphefumula kanye namandla okusebenzisa umzimba, ezinye zezinto ezingakhuphula umthwalo wengcindezi ye-oxidative okuyizemvelo zifaka:

  • Imisebe ye-UV kanye ne-ionizing
  • ukungcola
  • izinsimbi ezisindayo
  • izakhi zezitshalo
  • izidakamizwa
  • izibulala-zinambuzane
  • izimonyo
  • ukunambitheka
  • amakha
  • izithasiselo zokudla
  • amakhemikhali ezimboni
  • ukungcola kwemvelo

Konke lokhu kukhulisa kakhulu i-ROS futhi kubangele lokhu kungalingani esikubiza ngokuthi ukucindezeleka okwenziwe nge-oxidative. Ukucindezeleka kwe-oxidative kuholela ekulimazeni kwamangqamuzana nezicubu, futhi ubuchopho, ngokuvamile, buzwela kakhulu kukho.

Kodwa ubuchopho be-ADHD/ADD bukhulu nakakhulu. Cha, empeleni, futhi isezincwadini zocwaningo. Kodwa ngaphambi kokuba sixoxe ngalokho, ake sikhulume ngemithi esetshenziselwa ukwelapha i-ADHD.

Phezu kwayo yonke leyo mithombo yemvelo yokucindezeleka okwenziwe nge-oxidative echazwe ngenhla, yona kanye imithi yabantu yokwelapha izimpawu ze-ADHD ingabhebhethekisa inkinga. Ukusetshenziswa kwemithi ye-ADHD efana ne-Methylphenidate (MPH), ethengiswa njenge-Ritalin namanye amagama, kwandisa amazinga okucindezeleka okwenziwe nge-oxidative.

Ku-MPH kunobufakazi bokwenyuka kwe-OS, ukuzivikela kwe-AO okushintshiwe kanye nokuvuvukala kwe-neuro ezinganeni ze-ADHD

I-Kovacic, P., & Weston, W. I-Attention-deficit/hyperactivity disorder–unifying mechanism ehilela ukwelashwa kwe-antioxidant: I-Phenolics, izinhlobo ze-oxygen esebenzayo, nokucindezeleka kwe-oxidative. https://www.biochemjournal.com/articles/23/1-2-10-853.pdf

Ezincwadini zocwaningo, sibona amazinga aphezulu engcindezi ye-oxidative ebuchosheni be-ADHD, futhi lokhu kungase kuvele ekubeni sengozini ethile yofuzo ku-ROS.

Isibonelo salokhu ama-Organophosphates, njenge-dimethyl phosphate (DMP; isibulala-zinambuzane). Ucwaningo lwezofuzo lubonise ukuthi ukuchayeka emazingeni aphezulu ale nto endaweni kudale ingozi enkulu kakhulu yokuthuthukisa ezinye zezinguquko esizibona ku-ADHD ngama-dopamine receptors.

I-59% yamacala e-ADHD kubantwana abadalulwe yi-DMP abane- DRD4 I-GG genotype ibe ngenxa yokusebenzisana kofuzo nendawo ezungezile. Ngemuva kokulungiswa kwamanye ama-covariate, izingane eziphethe DRD4 I-GG genotype, yayichayeke emazingeni aphezulu e-DMP (ngaphezu kwe-median), futhi yaba ... nengozi eyanda kakhulu yokuthola i-ADHD

Chang, CH, et al., (2018). Ukusebenzisana phakathi kokuchayeka kwesibulala-zinambuzane se-organophosphate, ukucindezelwa kwe-oxidative, kanye ne-polymorphisms yofuzo ye-dopamine receptor D4 kwandisa ubungozi bokushoda kokunaka/ukuphazamiseka kwe-hyperactivity ezinganeni. https://doi.org/10.1016/j.envres.2017.10.011

Ngakho-ke ingcindezi ye-oxidative ingaba yingxenye ye-etiology (iqala kanjani) ye-ADHD. Kodwa ingabe inendima ekugcinweni kwayo? Ngingathi yebo. Kukhona ama-polymorphisms ezakhini zofuzo ezihlobene nokuvuvukala ezibonwa kulabo abane-ADHD. Amazinga e-antioxidant ancishisiwe abonakala ezinganeni, intsha, nakubantu abadala uma kuqhathaniswa namaqembu okulawula.

Ingcindezi ye-oxidative yinkinga ebuchosheni be-ADHD/ADD ukuthi ukwelashwa okudume kakhulu nokubikwa ukuthi kumnandi ukusetshenziswa kwama-OPC. Ama-OPC angama-antioxidants anamandla kakhulu. Ngaqala ukufunda ngabo kuwebhu yewebhu yamahhala e-Psychiatry Redefined, ongayibuka lapha. Angifuni ukuphuma esihlokweni, ngakho-ke ngeke ngingene kuma-OPC kulokhu okuthunyelwe kwebhulogi. Ungafunda kabanzi ngabo lapha:

Ingabe ama-OPC ayindlela yokwelapha ukudangala ngaphandle kwemithi?

Kodwa bengifuna ukuveza ukuthi ingcindezi ye-oxidative iyinhloso yokwelashwa kwezengqondo ezisebenzayo. Ungase ungabi nayo inzuzo yomuthi oqeqeshelwe imithi esebenzayo. Ngakho-ke ngishiya lolu lwazi lapha uma ufuna ukuhlola okwengeziwe ngohambo lwakho lwezempilo.

Kodwa njengoba sizofunda, kunezindlela eziningi ukuthi ukudla kwe-ketogenic kusiza ukwelapha ukucindezeleka okwenziwe nge-oxidative, ngaleyo ndlela kube (futhi cishe) ukuthuthukisa izimpawu zakho. Enye indlela i-keto engasiza ngayo i-ADHD.

Ukudla kwe-ketogenic kunciphisa kanjani amazinga okucindezeleka okwenziwe nge-oxidative kubantu abane-ADHD

Kunezindlela eziningi ezithonywa ngazo ukudla kwe-ketogenic. Esinye isibonelo ukuthi kukhona ukwanda i-agmatine, i-neurotransmitter ethandwa kancane eyenziwe nge-amino acid L-arginine. Lokhu kwanda kwe-agmatine ebuchosheni okwenzeka ekudleni kwe-ketogenic kunezinto ezibhalwe kahle ze-neuroprotective ezisiza ukuvikela ubuchopho be-ADHD emazingeni akhulayo okucindezeleka okwenziwe nge-oxidative.

Enye into okufanele uyazi mayelana nokudla kwe-ketogenic, mayelana nemiphumela yako ekucindezelekeni kwe-oxidative, ukuthi ama-ketones angumthombo wamandla ohlanzekile kakhulu. I-ROS encane idale ama-ketones avuthayo kaphethiloli kuneminye imithombo eyinhloko yamafutha. Ngenxa yalokhu, i-βHB (uhlobo lomzimba we-ketone) inciphisa ukukhiqizwa kwe-ROS futhi ikhulise izivikelo ze-antioxidant.

Enye indlela ukudla okune-ketogenic kusiza ngayo ukuphatha ngokuqondile ukucindezeleka kwe-oxidative ukuthi i-βHB inciphisa ukulimala kwe-oxidative ngenxa yokuthukwa kwe-excitotoxic (isb, khumbula i-glutamate?) endaweni lapho kwenzeka khona umonakalo. Ngandlela thize i-βHB isiza ukudambisa noma ukulungisa umonakalo owenziwe ingcindezi ye-oxidative. Futhi abacwaningi bacabanga ukuthi lokhu kungase kube ngenxa yomsebenzi othuthukisiwe we-mitochondrial noma ukuthonya ukubonakaliswa kofuzo.

Kodwa linda, kukhona okunye okwenziwa yi-ketogenic diet ukusiza ukunciphisa ukucindezeleka okwenziwe nge-oxidative.

Izidlo ze-Ketogenic zisisiza ukuthi senze i-antioxidant ebalulekile esiyenzayo emizimbeni yethu. Khumbula, sikhulume ngokuthi umzimba wakho wazi kanjani ukuthi i-ROS izoba yinto. Ngoba uyaphefumula futhi udle futhi unyakaze nokunye. Ngakho ngokusobala, inendlela yokubhekana nalokho. Futhi isebenzisana nalelo zinga elijwayelekile le-ROS ngento ebizwa ngeGlutathione. Kodwa njengoba sifundile, kunezinto eziningi endaweni yethu eziphusha indlela yethu ye-ROS idlule emazingeni alindelwe.

I-Glutathione iyi-antioxidant ebalulekile engavikela ingqamuzana emonakalweni we-DNA. Izidlo ze-Ketogenic zikusiza ukuthi wenze i-glutathione eyengeziwe ngokwandisa i-GCL, i-enzyme edingekayo ukuze kuhlanganiswe i-Glutathione. I-GCL ibhekwa “njenge-enzyme enciphisa isilinganiso,” okusho ukuthi uthola kuphela i-glutathione eningi njengoba unaleyo enzyme. Ngakho-ke, ukudla okune-ketogenic okwenza i-GCL eyengeziwe yikho okukunika i-glutathione eyengeziwe futhi ungumlingani onamandla kakhulu ekwehliseni ukucindezelwa kwe-oxidative ebuchosheni be-ADHD.

Isiphetho

Ngakho-ke usunakho. Lezo ezinye zezindlela eziningi ukuthi ukudla kwe-ketogenic kungasiza ekunciphiseni izimpawu ze-ADHD ne-ADD. Njengoba ubona, ukudla kwe-ketogenic ukungenelela okunezingqimba eziningi.

Ithuthukisa impilo ye-neuronal cell membrane, ithuthukise ukuxhumana phakathi kwamaseli. Izidlo ze-Ketogenic ziphakamisa i-GABA, kusiza ukuthuthukisa ukungalingani kwe-glutamate / GABA okubonwa kulesi sibalo.

Ama-ketones alawula (enze okwengeziwe) i-brain-derived neurotrophic factor (BDNF) ukwenza ukulungiswa kwamaseli e-neuronal. Khumbula, lawo ma-dopamine receptors awazilungisi ngokwawo. Kepha mhlawumbe okubaluleke kakhulu ukuthi ukumiswa kwe-BDNF kungayithuthukisa kanjani inkumbulo yokusebenza nokufunda kulabo abane-ADHD.

Izidlo ze-Ketogenic azigcini lapho.

Zinciphisa i-neuroinflammation futhi ziyi-neuroprotective, ezonciphisa ukucindezeleka okwenziwe nge-oxidative ebuchosheni be-ADHD.

Ukudla kwe-Ketogenic kuthuthukisa ukusebenza kwe-mitochondrial futhi kwakha umthombo wamandla omuhle kakhulu ezingxenyeni zobuchopho ezine-hypometabolic. Lokhu kukhiqizwa kwamandla okuthuthukisiwe kuzinzisa ulwelwesi lwe-neuronal (khumbula i-hyperpolarization?) futhi kuvumela amaseli ukuthi asebenze kangcono. Okungenzeka kunenzuzo enkulu ngokuhlukahluka kokuvezwa kwe-serotonin kanye ne-dopamine receptors nabathuthi ababonwa kulabo abane-ADHD ne-ADD.

Lezi yizo zonke izindawo zokuphulukisa okungenzeka ezihilelekile ezimpawu ze-ADHD.

Kodwa linda, ungase usho. Anginayo nje i-ADHD noma i-ADD. Nginezinkinga ze-commorbid, njengokuphazamiseka kwemizwa kanye nezinkinga zokusebenzisa kabi izidakamizwa. Lokhu ngeke kungimangaze. Lapho ukusebenza okuphezulu konakala, nganoma yisiphi isizathu, abantu banenkinga yokulawula imizwa. Udinga i-frontal lobe nebhalansi ye-neurotransmitter esebenza ngokugcwele ukuze ulawule imizwa yakho. Futhi ngenxa yokuthi ukudla okune-ketogenic kusiza ngalolo hlobo lwento, akufanele kukumangaze ukuthi nginokuthunyelwe okuhlukahlukene okuxoxa ngokuthi ukudla kwe-ketogenic nakho kusiza kanjani ukuphatha ukukhathazeka, ukudangala, kanye nokucindezeleka. ukuphazamiseka kokusebenzisa izidakamizwa.

Ukudla kwe-ketogenic kusiza kanjani ukuphazamiseka kokukhathazeka?
I-Ketogenic Diet Yelapha Utshwala
Ingabe i-keto ingakwazi ukwelapha ukudangala kwami ​​​​ngaphandle kwemithi?

Nakuba izinga lokunakekelwa kufanele lihlale linikezwa kuwe, kubalulekile futhi ukuthi wazi ezinye izinketho ezisekelwe ebufakazini. Ngakho ungenza izinqumo ezinolwazi mayelana nokunakekelwa kwabo.

Ngoba unelungelo lokwazi zonke izindlela ongazizwa ungcono ngazo.

Ukudla kwe-ketogenic kungenye yazo. Futhi kubalulekile kimina ukuthi othile akutshele lokho ukuze wenze izinqumo ezinolwazi mayelana nokwelashwa kwakho.

Ngifuna ukukukhuthaza ukuthi ufunde kabanzi mayelana nezinketho zakho zokwelapha kunoma yikuphi kwami blog izikhala. Ngibhala ngezindlela ezahlukahlukene ngamazinga ahlukahlukene emininingwane ongase ukuthole kuwusizo ukufunda ohambweni lwakho lwezempilo.

Yabelana ngalokhu okuthunyelwe kwebhulogi noma abanye nabangani nomndeni ohlushwa yizimpawu. Kwazise abantu ukuthi likhona ithemba.

Ungafunda okwengeziwe ngami lapha. Uma ungathanda ukusebenzisana nami ukuze usize ekushintsheni kwakho ekudleni kwe-ketogenic, ungakwenza lokho ngohlelo lwe-inthanethi engikunikezayo.

Uhlelo Lokubuyisela Inkungu Yengqondo

Ngijabulile, njengenjwayelo, ngethemba lokuthi ungazizwa ungcono.

Uyakuthanda lokho okufunda kubhulogi? Ingabe ufuna ukufunda ngama-webinars azayo, izifundo, ngisho nokunikezwa kosekelo oluzungezile nokusebenza nami ekufezeni imigomo yakho yokuphila kahle? Bhalisa ngezansi bese ulanda Umhlahlandlela wakho Wokudla Kwengqondo mahhala.

Free Brain Nutrition Guide

Okubhekwayo

Indlela Esebenzayo Yokugwema Ukuncipha Kwezidakamizwa Nezomsoco. (2020, Julayi 13). I-NBI. https://www.nbihealth.com/a-practical-approach-to-avoiding-drug-nutrient-depletions/

Achanta, LB, & Rae, CD (2017). I-β-Hydroxybutyrate ebuchosheni: I-Molecule eyodwa, Izindlela Eziningi. Ucwaningo lwe-Neurochemical, 42(1), i-35-49. https://doi.org/10.1007/s11064-016-2099-2

I-Adrenaline ne-Noradrenaline—Uyini Umehluko Nokufana? (nd). U-Andréas Astier. Ibuyiselwe ngoJanuwari 8, 2022, kusukela https://www.andreasastier.com/blog/adrenaline-and-noradrenaline-what-are-the-differences-and-similarities

Anand, D., Colpo, GD, Zeni, G., Zeni, CP, & Teixeira, AL (2017). I-Attention-Deficit/Hyperactivity Disorder Kanye Nokuvuvukala: Ulwazi Lwamanje Lusitshelani? Ukubuyekeza Okuhlelekile. Frontiers in Psychiatry, 8, 228. https://doi.org/10.3389/fpsyt.2017.00228

U-Arnsten, AFT (2000). I-Genetics ye-Childhood Disorders: XVIII. I-ADHD, Ingxenye 2: I-Norepinephrine Inethonya Elibalulekile Lokulinganisa Kumsebenzi We-Prefrontal Cortical. Ijenali ye-American Academy of Child & Adolescent Psychiatry, 39(9), i-1201-1203. https://doi.org/10.1097/00004583-200009000-00022

Badgaiyan, RD, Sinha, S., Sajjad, M., & Wack, DS (2015). I-Attenuated Tonic kanye Nokukhishwa Kwe-Phasic Okuthuthukisiwe kwe-Dopamine ku-Attenu Deficit Hyperactivity Disorder. I-PLOS ONE, 10(9), i-e0137326. https://doi.org/10.1371/journal.pone.0137326

U-Banerjee, S. (2013). I-Attention Deficit Hyperactivity Disorder Ezinganeni Nasentsheni. I-BoD - Izincwadi Ezifunwayo.

I-Bedford, A., & Gong, J. (2018). Imithelela ye-butyrate kanye nokuphuma kwayo empilweni yamathumbu nokukhiqizwa kwezilwane. Ukudla Kwezilwane (Zhongguo Xu Mu Shou Yi Xue Hui), 4(2), i-151-159. https://doi.org/10.1016/j.aninu.2017.08.010

U-Biederman, J., & Spencer, T. (1999). I-Attention-deficit/hyperactivity disorder (adhd) njenge-noradrenergic disorder. I-Psychiatry yezinto eziphilayo, 46(9), i-1234-1242. https://doi.org/10.1016/S0006-3223(99)00192-4

Boison, D. (2017). Ukuqonda okusha ezindleleni zokudla kwe-ketogenic. Umbono wamanje ku-Neurology, 30(2), i-187. https://doi.org/10.1097/WCO.0000000000000432

I-Metabolism yobuchopho empilweni, ukuguga, kanye ne-neurodegeneration. (2017). I-EMBO Journal, 36(11), i-1474-1492. https://doi.org/10.15252/embj.201695810

Bush, G. (2011a). I-Cingulate, Frontal, kanye Ne-Parietal Cortical Dysfunction in Attention-Deficit/Hyperactivity Disorder. I-Psychiatry yezinto eziphilayo, 69(12), i-1160-1167. https://doi.org/10.1016/j.biopsych.2011.01.022

Bush, G. (2011b). I-Cingulate, Frontal, kanye Ne-Parietal Cortical Dysfunction in Attention-Deficit/Hyperactivity Disorder. I-Psychiatry yezinto eziphilayo, 69(12), i-1160-1167. https://doi.org/10.1016/j.biopsych.2011.01.022

Carolina, CMM, PharmD, BCACP, BCGP Assistant Professor of Pharmacy Wingate University School of Pharmacy Wingate, North. (nd). Ukuncipha Komsoco Okubangelwa Yizidakamizwa: Okudingeka Bakwazi Osokhemisi. Ibuyiselwe ngoJanuwari 6, 2022, kusukela https://www.uspharmacist.com/article/druginduced-nutrient-depletions-what-pharmacists-need-to-know

I-cerebral glucose metabolism ku-hyperactivity. (1991). I-New England Journal of Medicine, 324(17), i-1216-1217. https://doi.org/10.1056/NEJM199104253241713

Chang, C.-H., Yu, C.-J., Du, J.-C., Chiou, H.-C., Chen, H.-C., Yang, W., Chung, M.- Y., Chen, Y.-S., Hwang, B., Mao, I.-F., & Chen, M.-L. (2018). Ukusebenzisana phakathi kokuchayeka kwesibulala-zinambuzane se-organophosphate, ukucindezelwa kwe-oxidative, kanye ne-polymorphisms yofuzo ye-dopamine receptor D4 kwandisa ubungozi bokushoda kokunaka/ukuphazamiseka kwe-hyperactivity ezinganeni. Ucwaningo lwezemvelo, 160, 339-346. https://doi.org/10.1016/j.envres.2017.10.011

U-Coffi, F., Adam, RHI, & Broersen, K. (2019). Izindlela ze-Molecular and Genetics of Oxidative Stress in Alzheimer's Disease. I-Journal yezifo ze-Alzheimer, 72(4), i-981. https://doi.org/10.3233/JAD-190863

Colucci-D'Amato, L., Speranza, L., & Volpicelli, F. (2020). I-Neurotrophic Factor BDNF, Imisebenzi Yezemvelo kanye Namandla Okwelapha Ekucindezelekeni, I-Neurodegeneration kanye Nomdlavuza Wobuchopho. I-International Journal of Sciences Molecular, 21(20), E7777. https://doi.org/10.3390/ijms21207777

I-Corona, JC (2020). Indima ye-Oxidative Stress kanye Neuroinflammation ku-Attention-Deficit/Hyperactivity Disorder. Antioxidants, 9(11). https://doi.org/10.3390/antiox9111039

Ama-Cytokines kanye Nobuchopho: Imithelela Yengqondo Yengqondo Yomtholampilo | I-American Journal of Psychiatry. (nd). Ibuyiselwe ngoJanuwari 8, 2022, kusukela https://ajp.psychiatryonline.org/doi/10.1176/appi.ajp.157.5.683?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed

Drake, J., Sultana, R., Aksenova, M., Calabrese, V., & Butterfield, DA (2003). Ukuphakama kwe-mitochondrial glutathione nge-γ-glutamylcysteine ​​ethyl ester ivikela i-mitochondria ekucindezelekeni kwe-oxidative eyenziwe yi-peroxynitrite. Ijenali yokucwaninga kwe-Neuroscience, 74(6), i-917-927. https://doi.org/10.1002/jnr.10810

U-Dunn, GA, Nigg, JT, & Sullivan, EL (2019a). I-Neuroinflammation njengesici esiyingozi sokunaka ukushoda kwe-hyperactivity disorder. I-Pharmacology, i-Biochemistry, kanye nokuziphatha, 182, 22-34. https://doi.org/10.1016/j.pbb.2019.05.005

U-Dunn, GA, Nigg, JT, & Sullivan, EL (2019b). I-Neuroinflammation njengesici esiyingozi sokunaka ukushoda kwe-hyperactivity disorder. Pharmacology Biochemistry kanye nokuziphatha, 182, 22-34. https://doi.org/10.1016/j.pbb.2019.05.005

Dvořáková, M., Sivoňová, M., Trebatická, J., Škodáček, I., Waczuliková, I., Muchová, J., & Ďuračková, Z. (2006). Umthelela we-polyphenolic extract kusuka ku-pine bark, i-Pycnogenol® ezingeni le-glutathione ezinganeni ezihlushwa ukuphazamiseka kwe-attention deficit hyperactivity disorder (ADHD). Umbiko we-Redox, 11(4), i-163-172. https://doi.org/10.1179/135100006X116664

U-Edden, RA, Crocetti, D., Zhu, H., Gilbert, DL, & Mostofsky, SH (2012). Ukugxila kwe-GABA okuncishisiwe ekunakekelweni-ukushoda/ukuphazamiseka kwe-hyperactivity. Izingobo zomlando zezifo zengqondo ezijwayelekile, 69(7), i-750-753. doi: I-10.1001 / archgenpsychiatry.2011.2280

U-Essa, MM, Subash, S., Braidy, N., Al-Adawi, S., Lim, CK, Manivasagam, T., & Guillemin, GJ (2013). Iqhaza le-NAD+, i-Oxidative Stress, kanye ne-Tryptophan Metabolism ku-Autism Spectrum Disorders. Ijenali Yamazwe Ngamazwe Yocwaningo Lwe-Tryptophan: IJTR, 6(Okwengeziwe 1), 15. https://doi.org/10.4137/IJTR.S11355

Fayed, NM, Morales, H., Torres, C., Fayed Coca, A., & Ángel Ríos, LF (2021). I-Brain Magnetic Resonance Imaging in Attention-Deficit/Hyperactivity Disorder (ADHD). Ku-P. Á. U-Gargiulo no-HL Mesones Arroyo (Eds.), Isibuyekezo Sezengqondo Nesayensi Yezinzwa: Ukusuka ku-Epistemology kuya ku-Clinical Psychiatry - Umq. IV: Umq. IV (amakhasi 623–633). Springer International Publishing. https://doi.org/10.1007/978-3-030-61721-9_44

Galic, MA, Riazi, K., & Pittman, QJ (2012). Ama-Cytokines kanye nokuthakasela kwengqondo. Frontiers e-Neuroendocrinology, 33(1), i-116. https://doi.org/10.1016/j.yfrne.2011.12.002

U-García-Rodríguez, D., & Giménez-Cassina, A. (2021). Imizimba Ye-Ketone Ebuchosheni Beyond Fuel Metabolism: Ukusuka Ekujabuleleni Kuya Ekuvezeni KweGene kanye Nokusayina Kweseli. Frontiers kwiMoleky Neuroscience, 14. https://doi.org/10.3389/fnmol.2021.732120

I-Gene-Environment Interaction—Uhlolojikelele | Izihloko zeSayensiDirect. (nd). Ibuyiselwe ngoJanuwari 9, 2022, kusukela https://www.sciencedirect.com/topics/earth-and-planetary-sciences/gene-environment-interaction

Hess, JL, Akutagava-Martins, GC, Patak, JD, Glatt, SJ, & Faraone, SV (2018a). Kungani kukhona ukukhubazeka okukhethiwe kwe-subcortical ku-ADHD? Izinkomba ezivela kudatha yokuchazwa kofuzo lobuchopho be-postmortem. I-Psychiatry yamaphilisi, 23(8), i-1787-1793. https://doi.org/10.1038/mp.2017.242

Hess, JL, Akutagava-Martins, GC, Patak, JD, Glatt, SJ, & Faraone, SV (2018b). Kungani kukhona ukukhubazeka okukhethiwe kwe-subcortical ku-ADHD? Izinkomba ezivela kudatha yokuchazwa kofuzo lobuchopho be-postmortem. I-Psychiatry yamaphilisi, 23(8), i-1787-1793. https://doi.org/10.1038/mp.2017.242

U-Hou, Y., Xiong, P., Gu, X., Huang, X., Wang, M., & Wu, J. (2018). I-Association of Serotonin Receptors With Attention Deficit Hyperactivity Disorder: Ukubuyekezwa Okuhlelekile kanye nokuhlaziywa kwe-Meta. Isayensi Yezokwelapha Yamanje, 38(3), i-538-551. https://doi.org/10.1007/s11596-018-1912-3

U-Jacintho, JD, & Kovacic, P. (2003). I-Neurotransmission ne-Neurotoxicity nge-Nitric Oxide, i-Catecholamines, ne-Glutamate: Izindikimba Ezihlanganisayo Zezinhlobo Ze-Oxygen Esebenzayo kanye Nokudluliselwa Kwe-Electron. I-Medicinal Chemistry Yamanje, 10(24), i-2693-2703. https://doi.org/10.2174/0929867033456404

Jonathan. (nd). Ukushoda Kwe-Micronutrient ku-ADHD: I-Global Research Consensus. I-ISOM. Ibuyiselwe ngoJanuwari 6, 2022, kusukela https://isom.ca/article/micronutrient-deficiencies-adhd-global-research-consensus/

UJoseph, N., Zhang-James, Y., Perl, A., & Faraone, SV (2015). I-Oxidative Stress kanye ne-ADHD: Ukuhlaziywa kwe-Meta. Ijenali Yezinkinga Zokunaka, 19(11), i-915-924. https://doi.org/10.1177/1087054713510354

Kapoor, D., Garg, D., & Sharma, S. (2021). Indima Ekhulayo Yezokwelapha Ze-Ketogenic Ngaphandle KweSithuthwane Ku-Child Neurology. Annals of Indian Academy of Neurology, 24(4), i-470. https://doi.org/10.4103/aian.AIAN_20_21

Kautzky, A., Vanicek, T., Philippe, C., Kranz, GS, Wadsak, W., Mitterhauser, M., Hartmann, A., Hahn, A., Hacker, M., Rujescu, D., Kasper , S., & Lanzenberger, R. (2020). Ukuhlukaniswa komshini wokufunda kwe-ADHD ne-HC ngedatha ye-multimodal serotonergic. Psychiatry yokuhumusha, 10(1), i-1-9. https://doi.org/10.1038/s41398-020-0781-2

Kerekes, N., Sanchéz-Pérez, AM, & Landry, M. (2021). I-Neuroinflammation njengesixhumanisi esingaba khona phakathi kwe-attention-deficit/hyperactivity disorder (ADHD) kanye nobuhlungu. Ama-Hypotheses Wezokwelapha, 157, 110717. https://doi.org/10.1016/j.mehy.2021.110717

Khansari, N., Shakiba, Y., & Mahmoudi, M. (2009). Ukuvuvukala okungapheli kanye nokucindezeleka okwenziwe nge-oxidative njengembangela enkulu yezifo ezihlobene nobudala nomdlavuza. Amalungelo Obunikazi Wakamuva Wokutholwa Kwezidakamizwa Zokuvuvukala nokungezwani komzimba, 3(1), i-73-80. https://doi.org/10.2174/187221309787158371

UKim, SW, Marosi, K., & Mattson, M. (2017). I-Ketone beta-hydroxybutyrate up-regulates BDNF expression ngokusebenzisa i-NF-κB njengempendulo eguquguqukayo ngokumelene ne-ROS, engase ithuthukise i-neuronal bioenergetics futhi ithuthukise i-neuroprotection (P3.090). Neurology, 88(16 Isengezo). https://n.neurology.org/content/88/16_Supplement/P3.090

Kovacic, P., & Weston, W. (nd). I-Attention-deficit/hyperactivity disorder - indlela ehlanganisayo ehlanganisa ukwelashwa kwe-antioxidant: I-Phenolics, izinhlobo ze-oxygen esebenzayo, kanye nengcindezi ye-oxidative.. 6.

Kovács, Z., D'Agostino, DP, Diamond, D., Kindy, MS, Rogers, C., & Ari, C. (2019a). Amandla Okwelapha E-Exogenous Ketone Supplement Eyenziwe I-Ketosis Ekwelapheni Izifo Zengqondo: Ukubuyekezwa Kwezincwadi Zamanje. Frontiers in Psychiatry, 10, 363. https://doi.org/10.3389/fpsyt.2019.00363

Kovács, Z., D'Agostino, DP, Diamond, D., Kindy, MS, Rogers, C., & Ari, C. (2019b). Amandla Okwelapha E-Exogenous Ketone Supplement Eyenziwe I-Ketosis Ekwelapheni Izifo Zengqondo: Ukubuyekezwa Kwezincwadi Zamanje. Frontiers in Psychiatry, 10, 363. https://doi.org/10.3389/fpsyt.2019.00363

I-Kronfol, Z., & Remick, DG (2000). Ama-Cytokines kanye Nobuchopho: Imiphumela Yengqondo Yomtholampilo. I-American Journal of Psychiatry, 157(5), i-683-694. https://doi.org/10.1176/appi.ajp.157.5.683

Kul, M., Unal, F., Kandemir, H., Sarkarati, B., Kilinc, K., & Kandemir, SB (2015). Ukuhlolwa kwe-Oxidative Metabolism Ezinganeni Nezintsha Ezincane Ezinokuntuleka Kokunaka I-Hyperactivity Disorder. Uphenyo Lwengqondo, 12(3), i-361-366. https://doi.org/10.4306/pi.2015.12.3.361

U-Lee, YH, & Song, GG (2018). Ukuhlaziywa Kwe-Meta Kokulawulwa Kwekesi kanye Nezinhlangano Ezisekelwe Emndenini Phakathi kwe-5-HTTLPR L/S Polymorphism kanye nokuba sengozini ku-ADHD. Ijenali Yezinkinga Zokunaka, 22(9), i-901-908. https://doi.org/10.1177/1087054715587940

Liu, D.-Y., Shen, X.-M., Yuan, F.-F., Guo, O.-Y., Zhong, Y., Chen, J.-G., Zhu, L.- Q., & Wu, J. (2015a). IPhysiology ye-BDNF kanye Nobudlelwano Bayo ne-ADHD. I-Molecular Neurobiology, 52(3), i-1467-1476. https://doi.org/10.1007/s12035-014-8956-6

Liu, D.-Y., Shen, X.-M., Yuan, F.-F., Guo, O.-Y., Zhong, Y., Chen, J.-G., Zhu, L.- Q., & Wu, J. (2015b). IPhysiology ye-BDNF kanye Nobudlelwano Bayo ne-ADHD. I-Molecular Neurobiology, 52(3), i-1467-1476. https://doi.org/10.1007/s12035-014-8956-6

U-Liu, H., Wang, J., He, T., Becker, S., Zhang, G., Li, D., & Ma, X. (2018). I-Butyrate: Inkemba Esika Kabili Yezempilo? Intuthuko kwezokudla (Bethesda, Md.), 9(1), i-21-29. https://doi.org/10.1093/advances/nmx009

U-Lussier, DM, Woolf, EC, Johnson, JL, Brooks, KS, Blattman, JN, & Scheck, AC (2016). Ukuzivikela okuthuthukisiwe kumodeli yegundane ye-glioma eyingozi kulamula ukudla kwe-ketogenic yokwelapha. Umdlavuza we-BMC, 16(1), i-310. https://doi.org/10.1186/s12885-016-2337-7

Maltezos, S., Hoorder, J., Coghlan, S., Skirrow, C., O'Gorman, R., Lavender, TJ, Mendez, MA, Mehta, M., Daly, E., Xenitidis, K., Paliokosta, E., Spain, D., Pitts, M., Asherson, P., Lythgoe, DJ, Barker, GJ, & Murphy, DG (2014). I-Glutamate/glutamine kanye nobuqotho be-neuronal kubantu abadala abane-ADHD: Ucwaningo lwe-proton MRS. Psychiatry yokuhumusha, 4(3), e373-e373. https://doi.org/10.1038/tp.2014.11

UMamiya, PC, Arnett, AB, & Stein, MA (2021a). Ukunakekelwa Kwezokwelapha Okuqondile ku-ADHD: Icala Le-Neural Excitation and Inhibition. I-Brain Sciences, 11(1), i-91. https://doi.org/10.3390/brainsci11010091

UMamiya, PC, Arnett, AB, & Stein, MA (2021b). Ukunakekelwa Kwezokwelapha Okuqondile ku-ADHD: Icala Le-Neural Excitation and Inhibition. I-Brain Sciences, 11(1), i-91. https://doi.org/10.3390/brainsci11010091

Martins, MR, Reinke, A., Petronilho, FC, Gomes, KM, Dal-Pizzol, F., & Quevedo, J. (2006). Ukwelashwa kwe-methylphenidate kudala ingcindezi ye-oxidative ebuchosheni begundane elincane. Ucwaningo lweBongo, 1078(1), i-189-197. https://doi.org/10.1016/j.brainres.2006.01.004

Merker, S., Reif, A., Ziegler, GC, Weber, H., Mayer, U., Ehlis, A.-C., Conzelmann, A., Johansson, S., Müller-Reible, C., Nanda , I., Haaf, T., Ullmann, R., Romanos, M., Fallgatter, AJ, Pauli, P., Strekalova, T., Jansch, C., Vasquez, AA, Haavik, J., … Lesch, K.-P. (2017a). I-SLC2A3 i-polymorphism eyodwa-nucleotide kanye nokuphindaphinda kuthonya ukucubungula kwengqondo kanye nengozi eqondene nenani labantu yokunganaki-ukushoda/ukuphazamiseka kokusebenza ngokweqile. I-Journal ye-Child Psychology ne-Psychiatry, 58(7), i-798-809. https://doi.org/10.1111/jcpp.12702

Merker, S., Reif, A., Ziegler, GC, Weber, H., Mayer, U., Ehlis, A.-C., Conzelmann, A., Johansson, S., Müller-Reible, C., Nanda , I., Haaf, T., Ullmann, R., Romanos, M., Fallgatter, AJ, Pauli, P., Strekalova, T., Jansch, C., Vasquez, AA, Haavik, J., … Lesch, K.-P. (2017b). I-SLC2A3 i-polymorphism eyodwa-nucleotide kanye nokuphindaphinda kuthonya ukucubungula kwengqondo kanye nengozi eqondene nenani labantu yokunganaki-ukushoda/ukuphazamiseka kokusebenza ngokweqile. Ijenali ye-Psychology Yezingane kanye ne-Psychiatry, kanye ne-Allies Disciplines, 58(7), i-798-809. https://doi.org/10.1111/jcpp.12702

Millenet, SK, Nees, F., Heintz, S., Bach, C., Frank, J., Vollstädt-Klein, S., Bokde, A., Bromberg, U., Büchel, C., Quinlan, EB, Desrivières, S., Fröhner, J., Flor, H., Frouin, V., Garavan, H., Gowland, P., Heinz, A., Ittermann, B., Lemaire, H., … Hohmann, S. (2018). I-COMMT Val158Met Polymorphism kanye Nokukhubazeka Komphakathi Ngokusebenzisana Kuthinta Izimpawu Zokunaka-Ukuntuleka Kokusebenza Okukhulu Entsheni Enempilo. Imingcele kuGenetics, 9, 284. https://doi.org/10.3389/fgene.2018.00284

Millichap, J. (1990). I-Cerebral Glucose Metabolism kanye ne-ADHD. I-Pediatric Neurology Briefs, 4(11), i-83-84. https://doi.org/10.15844/pedneurbriefs-4-11-4

UMurphy, P., & Burnham, WM (2006). Ukudla kwe-ketogenic kubangela ukwehla okubuyiseleka emuva ezingeni lomsebenzi kumagundane e-Long-Evans. I-Experimental Neurology, 201(1), i-84-89. https://doi.org/10.1016/j.expneurol.2006.03.024

I-Neuroinflammation njengesixhumanisi esingaba khona phakathi kokunaka-ukushoda/ukuphazamiseka kwe-hyperactivity (ADHD) nobuhlungu | I-Elsevier Enhanced Reader. (nd). https://doi.org/10.1016/j.mehy.2021.110717

Ucwaningo Olusha Nge-Keto Diet kanye ne-GLUT1 Deficiency Syndrome. (2020, February 19). Ketogenic.Com. https://ketogenic.com/glut1-deficiency-syndrome/

Nikolaidis, A., & Gray, JR (2010). I-ADHD kanye ne-DRD4 exon III 7-repeat polymorphism: Ukuhlaziywa kwemeta kwamazwe ngamazwe. I-Social Cognitive and Affective Neuroscience, 5(2-3), i-188-193. https://doi.org/10.1093/scan/nsp049

Norwitz, NG, Hu, MT, & Clarke, K. (2019). Izindlela I-Ketone Body D-β-Hydroxybutyrate Ingase Zithuthukise Ngazo I-Multiple Cellular Pathologies ye-Parkinson's Disease. Imingcele Kwezokudla, 6, 63. https://doi.org/10.3389/fnut.2019.00063

Ukuncipha Komsoco. (nd). I-BioMed Wellness Centre. Ibuyiselwe ngoJanuwari 6, 2022, kusukela https://wellnessbiomed.com/pages/nutrient-depletion

U-Paoli, A. (2020). Isifundo Sokulinga: Ukudla Kwe-Ketogenic Njengesici Esivikelayo Ngesikhathi Sokutheleleka kwe-SARS-CoV-2 (I-Clinical Trial Registration No. NCT04615975). Clinictrials.gov. https://clinicaltrials.gov/ct2/show/NCT04615975

Peng, W., Tan, C., Mo, L., Jiang, J., Zhou, W., Du, J., Zhou, X., Liu, X., & Chen, L. (2021). I-Glucose transporter 3 ku-neuronal glucose metabolism: Impilo nezifo. umzimba, 123, 154869. https://doi.org/10.1016/j.metabol.2021.154869

I-Pizzino, G., Irrera, N., Cucinotta, M., Pallio, G., Mannino, F., Arcoraci, V., Squadrito, F., Altavilla, D., & Bitto, A. (2017). I-Oxidative Stress: Izingozi Nezinzuzo Zempilo Yomuntu. Imithi Ye-Oxidative kanye Nokuphila Kade Kweselula, 2017. https://doi.org/10.1155/2017/8416763

U-Pizzorno, J. (2014). I-Mitochondria—Ibalulekile Ekuphileni Nasempilweni. Imithi Edidiyelwe: Ijenali Yomtholampilo, 13(2), i-8.

Purkayastha, P., Malapati, A., Yogeeswari, P., & Sriram, D. (2015). Ukubuyekezwa kokuthi GABA/Glutamate Pathway for Therapeutic Intervention of ASD and ADHD. I-Medicinal Chemistry Yamanje, 22(15), i-1850-1859.

Ubeka, NA, Ryan, M., Oeltzschner, G., Horska, A., Edden, RAE, & Mahone, EM (2020). Kuncishiswe i-striatal GABA kubantwana abangahlosiwe abane-ADHD ku-7T. Ucwaningo Lwengqondo: I-Neuroimaging, 301, 111082. https://doi.org/10.1016/j.pscychresns.2020.111082

U-Réus, GZ, Scaini, G., Titus, SE, Furlanetto, CB, Wessler, LB, Ferreira, GK, Gonçalves, CL, Jeremias, GC, Quevedo, J., & Streck, EL (2015). I-Methylphenidate inyusa ukumuncwa kwe-glucose ebuchosheni bamagundane amancane nabadala. Imibiko Yezemithi, 67(5), i-1033-1040. https://doi.org/10.1016/j.pharep.2015.03.005

Saccaro, LF, Schilliger, Z., Perroud, N., & Piguet, C. (2021). Ukuvuvukala, Ukukhathazeka, kanye Nengcindezi Ekunakeni-Ukushoda/I-Hyperactivity Disorder. Ama-Biomedicines, 9(10), i-1313. https://doi.org/10.3390/biomedicines9101313

Schmitz, F., Silveira, J., Venturin, G., Greggio, S., Schu, G., Zimmer, E., Dacosta, J., & Wyse, A. (2021). Ubufakazi Bokuthi Ukwelashwa Kwe-Methylphenidate Kuvusa Ukukhathazeka Okufana Nokuziphatha Ngokusebenzisa I-Glucose Hypometabolism kanye Nokuphazamiseka Kwe-Orbitofrontal Cortex Metabolic Networks. Ucwaningo lwe-Neurotoxicity, 39. https://doi.org/10.1007/s12640-021-00444-9

Sengupta, SM, Grizenko, N., Thakur, GA, Bellingham, J., DeGuzman, R., Robinson, S., TerStepanian, M., Poloskia, A., Shaheen, SM, Fortier, M.-E., U-Choudhry, Z., & Joober, R. (2012). Ukuhlangana okuhlukile phakathi kofuzo lwe-norepinephrine transporter kanye ne-ADHD: Indima yocansi kanye ne-subtype. Ijenali yePsychiatry & Neuroscience : JPN, 37(2), i-129. https://doi.org/10.1503/jpn.110073

Seyedi, M., Gholami, F., Samadi, M., Djalali, M., Effatpanah, M., Yekaninejad, MS, Hashemi, R., Abdolahi, M., Chamari, M., & Honarvar, NM (2019) ). Umphumela Wokwengezwa kwe-Vitamin D3 ku-Serum BDNF, i-Dopamine, ne-Serotonin Ezinganeni Ezinenkinga Yokunaka-Ukuntuleka/Ukungasebenzi Kwe-Hyperactivity. I-CNS & Neurological Disorders - Okuhlosiwe Kwezidakamizwa- I-CNS & Neurological Disorders), 18(6), i-496-501. https://doi.org/10.2174/1871527318666190703103709

Sheehan, K., Lowe, N., Kirley, A., Mullins, C., Fitzgerald, M., Gill, M., & Hawi, Z. (2005). Izinhlobo zofuzo ze-Tryptophan hydroxylase 2 (TPH2) ezihlotshaniswa ne-ADHD. I-Psychiatry yamaphilisi, 10(10), i-944-949. https://doi.org/10.1038/sj.mp.4001698

Sigurdardottir, HL, Kranz, GS, Rami-Mark, C., James, GM, Vanicek, T., Gryglewski, G., Kautzky, A., Hienert, M., Traub-Weidinger, T., Mitterhauser, M. , Wadsak, W., Hacker, M., Rujescu, D., Kasper, S., & Lanzenberger, R. (2016). Imithelela yokuhlukahluka kofuzo lwe-norepinephrine transporter ekubopheni kwe-NET ku-ADHD nezilawuli ezinempilo eziphenywa yi-PET. Ibalazwe le-Brain Mapping, 37(3), i-884-895. https://doi.org/10.1002/hbm.23071

U-Stilling, RM, van de Wouw, M., Clarke, G., Stanton, C., Dinan, TG, & Cryan, JF (2016). I-neuropharmacology ye-butyrate: Isinkwa nebhotela ye-microbiota-gut-brain axis? I-Neurochemistry International, 99, 110-132. https://doi.org/10.1016/j.neuint.2016.06.011

I-Striatum-Uhlolojikelele | Izihloko zeSayensiDirect. (nd). Ibuyiselwe ngoJanuwari 7, 2022, kusukela https://www.sciencedirect.com/topics/psychology/striatum

Stuart, CA, Ross, IR, Howell, MEA, McCurry, MP, Wood, TG, Ceci, JD, Kennel, SJ, & Wall, J. (2011). I-Brain Glucose Transporter (Glut3) I-Haploinsufficiency Ayiphazamisi Ukutholwa kweGlucose ye-Mouse Brain. Ucwaningo lweBongo, 1384, 15. https://doi.org/10.1016/j.brainres.2011.02.014

I-Neuropharmacology ye-Ketogenic Diet e-DuckDuckGo. (nd). Ibuyiselwe ngoJanuwari 8, 2022, kusukela https://duckduckgo.com/?q=The+Neuropharmacology+of+the+Ketogenic+Diet&atb=v283-1&ia=web

Ułamek-Kozioł, M., Czuczwar, SJ, Januszewski, S., & Pluta, R. (2019). Ukudla Kwe-Ketogenic kanye Nesithuthwane. Amakhemikhali, 11(10). https://doi.org/10.3390/nu11102510

Vergara, RC, Jaramillo-Riveri, S., Luarte, A., Moënne-Loccoz, C., Fuentes, R., Couve, A., & Maldonado, PE (2019). Isimiso Se-Energy Homeostasis: I-Neuronal Energy Regulation Drives Local Network Dynamics Generating Behaviour. Imingcele ku-Computational Neuroscience, 13. https://doi.org/10.3389/fncom.2019.00049

Ukudla okune-carbohydrate ephansi kakhulu kuthuthukisa ukungatheleleki kwe-T-cell yomuntu ngokuhlelwa kabusha kwe-immunometabolic. (2021). I-EMBO Molecular Medicine, 13(8), i-e14323. https://doi.org/10.15252/emmm.202114323

Ayini ama-xenobiotics nezibonelo zawo? (nd). Ibuyiselwe ngoJanuwari 9, 2022, kusukela https://psichologyanswers.com/library/lecture/read/98518-what-are-xenobiotics-and-their-examples

Wiers, CE, Lohoff, FW, Lee, J., Muench, C., Freeman, C., Zehra, A., Marenco, S., Lipska, BK, Auluck, PK, Feng, N., Sun, H. , Goldman, D., Swanson, JM, Wang, G.-J., & Volkow, ND (2018). I-Methylation yofuzo lwe-dopamine transporter egazini ihlotshaniswa nokutholakala kwe-striatal dopamine transporter ku-ADHD: Ucwaningo lokuqala. I-European Journal ye-Neuroscience, 48(3), i-1884-1895. https://doi.org/10.1111/ejn.14067

I-Włodarczyk, A., Wiglusz, MS, & Cubała, WJ (2018). Ukudla kwe-Ketogenic kwe-schizophrenia: indlela yokudla okunomsoco ekwelashweni kwe-antipsychotic. Ama-Hypotheses Wezokwelapha, 118, 74-77. https://doi.org/10.1016/j.mehy.2018.06.022

U-Xu, W., Gao, L., Li, T., Shao, A., & Zhang, J. (2018). Indima ye-Neuroprotective ye-Agmatine ku-Neurological Diseases. I-Neuropharmacology yamanje, 16(9), i-1296. https://doi.org/10.2174/1570159X15666170808120633

Yokokura, M., Takebasashi, K., Takao, A., Nakaizumi, K., Yoshikawa, E., Futatsubashi, M., Suzuki, K., Nakamura, K., Yamasue, H., & Ouchi, Y. (2021). I-invivo imaging ye-dopamine D1 receptor kanye ne-microglia ecushiwe ekunakekelweni-ukulahlekelwa / ukuphazamiseka kwe-hyperactivity: Ucwaningo lwe-positron emission tomography. I-Psychiatry yamaphilisi, 26(9), i-4958-4967. https://doi.org/10.1038/s41380-020-0784-7

Zametkin, AJ, Nordahl, TE, Gross, M., King, AC, Semple, WE, Rumsey, J., Hamburger, S., & Cohen, RM (1990). I-cerebral glucose metabolism kubantu abadala abane-hyperactivity yokuqala yobuntwana. I-New England Journal of Medicine, 323(20), i-1361-1366. https://doi.org/10.1056/NEJM199011153232001

Zhang, S., Wu, D., Xu, Q., Wena, L., Zhu, J., Wang, J., Liu, Z., Yang, L., Tong, M., Hong, Q., no-Chi, X. (2021). Umthelela wokuvikela kanye nendlela engaba khona ye-NRXN1 ekufundeni nasekukhumbuleni kumamodeli wamagundane e-ADHD. I-Experimental Neurology, 344, 113806. https://doi.org/10.1016/j.expneurol.2021.113806

U-Zhou, R., Wang, J., Han, X., Ma, B., Yuan, H., & Song, Y. (2019). I-Baicalin ilawula uhlelo lwe-dopamine ukulawula izimpawu eziyinhloko ze-ADHD. I-Molecular Brain, 12(1), i-11. https://doi.org/10.1186/s13041-019-0428-5

(Nd). Ibuyiselwe ngoJanuwari 7, 2022, kusukela https://www.mind-diagnostics.org/blog/adhd/finding-the-connection-between-dopamine-and-adhd